Recursion Pharmaceuticals reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experienced widening net losses. The release of their Boltz-2 model underscored a ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...

Forbes contributors publish independent expert analyses and insights. I write about the business of healthcare. This article is more than 5 years old. Chris Gibson, Co-Founder & CEO, Recursion ...

Stella Osoba is the Senior Editor of trading and investing at Investopedia. She co-founded and chaired Women in Technical Analysis. She has 15+ years of experience as a financial writer and technical ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Explore Recursion Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RXRX. Recursion reported second-quarter revenue of $19.22 million, beating ...

First Light News: Fed Lowers Rate and Hints at Further Easing This YearThu, 18 Sep 2025 09:37:56 GMT Money Flows Show Why e.l.f. Beauty Shares SoarThu, 18 Sep 2025 09:24:41 GMT Money Flows Help Find ...

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was triggered by the initiation of additional preclinical ...